Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Feng'e Ma"'
Autor:
Li Pingping, Zeng Shulan, Hongbin Sun, Feng'e Ma, Jingjing Li, Li Liangping, Guohai Zhang, Erguang Li
Publikováno v:
Biochemical Pharmacology. 163:133-141
Palbociclib is a Cdk4/6 inhibitor approved for metastatic estrogen receptor-positive breast cancer. The drug is also under clinical evaluation for metastatic urothelial cancer and other solid tumors. Preclinical studies from multiple tumor types sugg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af23ba5ddda835e372391f5bde82b9f5
https://doi.org/10.1016/j.bcp.2019.02.017
https://doi.org/10.1016/j.bcp.2019.02.017
Autor:
Yang Jingmei, Li Liangping, Yan Peng, Lu Xing, Ye Zhang, Ying-Ming Pan, Qing-Ling Ni, Wu Yiming, Sheng Chen, Feng'e Ma, Xue Hong
Publikováno v:
European Journal of Medicinal Chemistry. 151:226-236
A series of 2(1H)-quinolinone derivatives and their rhodium (III) complexes were designed and synthesized. All the rhodium (III) complexes exhibited higher in vitro cytotoxicity for Hep G2, HeLa 229, MGC80-3, and NCI-H460 human tumor cell lines than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69ea63c783bf776a6083ea099fd62df6
https://doi.org/10.1016/j.ejmech.2018.03.074
https://doi.org/10.1016/j.ejmech.2018.03.074
Autor:
Yan-hong Zhu, Yang Jingmei, Yan Peng, Lu Xing, Li Liangping, Shi Zhenhao, Yang Yang, Huang Kunyuan, Xue Hong, Sheng Chen, Ping Jiang, Feng'e Ma, Wu Yiming
Publikováno v:
MedChemComm. 9:100-107
A novel nickel(ii) complex of 6-methoxy-1-pyridine-β-carboline (4a) was synthesized and characterized. The cytotoxicities of the complex towards six cancer cell lines, including MGC-803, Hep G2, T24, OS-RC-2, NCI-H460, and SK-OV-3, and human normal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::694eea5a40ae28d44a97e8044fb31e91
https://doi.org/10.1039/c7md00428a
https://doi.org/10.1039/c7md00428a
Autor:
Guo-Hai Zhang, Yan-Cheng Liu, Lu Xing, Yun-Feng An, Wu Yiming, Hui Zhong, Yan Peng, Zhen-Feng Chen, Feng'e Ma, Yang Jingmei, Yan-hong Zhu, Zu-Ping Zhou
Publikováno v:
Journal of Biological Chemistry. 291:4211-4225
p53 inactivation is a hallmark in non-small-cell lung cancer (NSCLC). It is therefore highly desirable to develop tumor-specific treatment for NSCLC therapy by restoring p53 function. Herein, a novel naphthalimide compound, NA-17, was identified as a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc320c1f361ff2c87ee00c462d3a497c
https://doi.org/10.1074/jbc.m115.669978
https://doi.org/10.1074/jbc.m115.669978
Publikováno v:
Molecular medicine reports. 18(5)
Chemotherapy resistance, the molecular mechanism of which is complex and has not been fully understood, poses a major challenge in the treatment of patients with non‑small cell lung cancer (NSCLC). The dysregulation of microRNAs (miRs) has been rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6603f566a3881f8a7d10bc5b05663257
https://pubmed.ncbi.nlm.nih.gov/30221716
https://pubmed.ncbi.nlm.nih.gov/30221716
Autor:
Guohai Zhang1, Yunfeng An1, Xing Lu1, Hui Zhong1, Yanhong Zhu1, Yiming Wu1, Feng'e Ma1, Jingmei Yang1, Yancheng Liu1, Zuping Zhou1, Yan Peng1 pengyan630@gxnu.edu.cn, Zhenfeng Chen1 chenzf@gxnu.edu.cn
Publikováno v:
Journal of Biological Chemistry. 2/19/2016, Vol. 291 Issue 8, p4211-4225. 15p.